对于可切除胰腺癌的辅助/非辅助疗法的发展概念
John M Bryant1, Luis Ruffolo2, Kevin Soares2
1Department of Radiation Oncology, Section of Gastrointestinal Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
The Journal of clinical investigation
|July 15, 2025
概括
胰腺管腺癌 (PDAC) 仍然难以治愈. 本综述探讨了新的全身疗法,辐射技术和癌症疫苗,以改善可操作PDAC的治疗.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 癌症研究 癌症研究
背景情况:
- 胰腺管腺癌 (PDAC) 在瘤学中是一个重大挑战,尽管多学科护理进展,但治疗选择有限.
- 目前对可操作的PDAC的治疗策略需要不断发展以改善患者的治疗结果.
研究的目的:
- 审查在可手术胰腺管腺癌 (PDAC) 的管理中不断发展的概念.
- 讨论辅助和新辅助全身疗法,放射治疗和癌症疫苗在PDAC治疗中的作用.
主要方法:
- 关于PDAC系统疗法,放射瘤学和癌症疫苗的最新进展的文献综述.
- 对新兴生物标志物和向疗法的分析,包括KRAS抑制剂.
- 评估辐射输送和个性化疫苗生产的技术进步.
主要成果:
- 辅助和新辅助系统疗法正在发展,提供新的治疗范式.
- 放射治疗仍然是PDAC管理的一个有争议但重要的组成部分.
- 癌症疫苗,特别是个性化的疫苗,显示出PDAC治疗的新希望.
结论:
- 生物标志物,KRAS抑制剂,精确辐射和个性化疫苗方面的进展表明,可操作的PDAC护理指南正在迅速改变.
- 未来可操作的PDAC的管理可能将包含更有针对性和个性化的治疗方法.
- 通过生物标志物改善治疗反应的预测对于优化PDAC治疗策略至关重要.
相关概念视频
01:29Chronic Pancreatitis II: Collaborative Care
130
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
130
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K